Evidence map›Paper›PMID 41068485›Full record

ArticleLeukemia2025

Distinct characteristics of VEXAS-causative UBA1 M41 and recurrent functional non-M41 mutations.

Maki Sakuma, Amy K Wang, Samuel J Magaziner, Sachiko P Keane, Manja Meggendorfer, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, David B Beck, Wencke Walter

Abstract read
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. VEXAS syndrome.Nature reviews. Disease primers · 2026
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maki Sakuma *Munich Leukemia Laboratory, Munich, Germany.ORCID 0000-0001-7579-6232
Amy K Wang *Center for Human Genetics and Genomics, NYU School of Medicine, New York, NY, USA.ORCID 0009-0005-9727-7552
Samuel J MagazinerCenter for Human Genetics and Genomics, NYU School of Medicine, New York, NY, USA.ORCID 0000-0002-5345-217X
Sachiko P KeaneCenter for Human Genetics and Genomics, NYU School of Medicine, New York, NY, USA.
Manja MeggendorferMunich Leukemia Laboratory, Munich, Germany.ORCID 0000-0002-9038-3265
Wolfgang KernMunich Leukemia Laboratory, Munich, Germany.ORCID 0000-0002-6452-2874
Claudia HaferlachMunich Leukemia Laboratory, Munich, Germany.ORCID 0000-0002-6333-5049
Torsten HaferlachMunich Leukemia Laboratory, Munich, Germany.ORCID 0000-0003-0196-2837
David B Beck *Center for Human Genetics and Genomics, NYU School of Medicine, New York, NY, USA.ORCID 0000-0002-5884-6231
Wencke Walter *Munich Leukemia Laboratory, Munich, Germany. wencke.walter@mll.com.ORCID 0000-0002-5083-9838

Funding

Understanding the Role of Somatic Mutations in Adult Inflammatory DiseasesR00AR078205 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BECK, DAVID · 2022 to 2024
$740k
EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020) 953407NIAMS NIH HHS R00 AR078205U.S. Department of Defense (United States Department of Defense) BMFRP-IDA HT9425-23-1-0507U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (National Cancer Institute Division of Cancer Epidemiology and Genetics) R00AR078205
6 · The paper itself

Abstract

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a severe inflammatory and hematologic disease caused by somatic mutations in UBA1. Canonical pathogenic mutations at UBA1 p.Met41 (M41) lead to the loss of the cytoplasmic isoform (UBA1b), while non-canonical mutations outside of M41 (non-M41) result in reduced activity of both nuclear and cytoplasmic isoforms. Studies have reported clinical differences between canonical and non-canonical mutations, but these findings are constrained by small sample sizes and scarcity of genetic studies. In our study, we screened 29,000 individuals for UBA1 variants, referred for a broad range of hematologic diseases, and subjected to 62-gene panel sequencing, identifying 232 patients carrying likely disease-causing mutations. We identified decreased polyubiquitylation in all of the 18 UBA1 variants tested and found differences in H2A/B monoubiquitylation alteration between M41 and non-M41 mutations. Our findings confirm that patients harboring M41 mutations present at most with myelodysplastic neoplasms (MDS) and suggest that M41 mutations generally do not tolerate multiple co-mutations. In contrast, non-M41 mutations are more likely to appear with co-mutations and are detected in patients with hematologic neoplasms other than MDS. Our study establishes that M41 and non-M41 mutations exhibit distinct clinical and biological phenotypes, significantly enhancing UBA1 variant interpretation.

Indexed as

MutationUbiquitin-Activating EnzymesFemaleHumansMaleMyelodysplastic SyndromesSkin Diseases, GeneticUBA1 protein, humanUbiquitin-Activating Enzymes

Identifiers

PMID41068485
PMCPMC12634433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.